ArticleLife (Basel, Switzerland)2026
Analysis of Pediatric Secondary Glaucoma Patients Treated with Micropulse Transscleral Cyclophotocoagulation (MP-TSCPC).
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSecondary glaucoma in children results from congenital or acquired ocular abnormalities, systemic diseases, or syndromes. These conditions impair aqueous humor outflow despite an open iridocorneal angle, causing elevated intraocular pressure (IOP). Micropulse transscleral cyclophotocoagulation (MP-TSCPC) reduces aqueous humor production by targeting the ciliary body and restores the aqueous humor's circulation balance. The aim of the study was to evaluate the safety and efficacy of MP-TSCPC in pediatric secondary glaucoma.
methodsThis retrospective study included 59 children who underwent MP-TSCPC procedures. The mean age was 7.2 years (range 4 months-17 years). Data on IOP, prior glaucoma treatments, medication use, and adverse events were analyzed. The mean follow-up was 10.4 months.
resultsThe mean preoperative IOP was 34.0 mmHg, which significantly decreased to 25.8 mmHg after MP-TSCPC, representing a mean reduction of 20.8% (
conclusionsMP-TSCPC effectively lowers IOP in pediatric secondary glaucoma and has a favorable safety profile. The option for repeated treatments and reduced medication needs supports its use as a less invasive alternative to conventional surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.